Global Developments in Germany, Canada and Brazil
Germany has approved a large phase 2b study on psilocybin for treatment-resistant depression.
Dr. Gerhard Gründer, of the Central Institute of Mental Health Mannheim, will lead the study alongside the Department of Psychiatry and Psychotherapy at Charité Campus Berlin Mitte and the Mind Foundation.
The German Government is funding the trials with €2 million allocated from the Federal Ministry of Education and Research.
This represents the first significant milestone in psilocybin clinical research for depression in Germany since the 1970s.
In Canada, the government has allowed the first Section 56 exemption to grant psilocybin therapy to a non-palliative patient, Psilocybin Alpha reported. This is another milestone (and key legal precedent) in the country’s path towards federal decriminalization of the compound, just over three months after Minister of Health Patty Hajdu granted the first exception to four terminally-ill patients.
The treatment was provided by Dr. Bruce Tobin, founder of TheraPsil, an NGO working to allow legal access to psilocybin therapy in Canada.
In Brazil, the National Health Surveillance Agency (ANVISA) approved the use of Spravato, an esketamine nasal spray used to treat treatment-resistant depression and acute suicidal behavior. The drug was …